BioSpace News Archive

Despite its lofty valuation, the company does not yet have any drugs in the clinic, although it expects to submit Investigational New Drug applications in 2022 and 2023.

Will there be enough doses of the two authorized mRNA COVID-19 vaccines to meet the lofty goal of 100 million inoculations within 100 days of the start of Joe Biden’s presidential administration?

Daiichi Sankyo’s and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has become the first HER2-directed medication approved to treat gastric cancer in the U.S. in 10 years.

LexaGene has begun a series of studies aimed to bring its MiQLab from research-only use to point-of-care use to detect the SARS-CoV-2 virus.

The U.S. Food and Drug Administration approved Janssen Pharmaceuticals’ Darzalex Faspro for adults with newly diagnosed light chain amyloidosis.

n-Lorem Foundation has taken on a challenge that many nations consider too great: treating patients with ultra-rare diseases (which affect 30 or fewer people) for free, for life.

Being studied for GAD, OCD, AD and spinocerebellar ataxia, Biohaven’s troriluzole has now struck out in 3 late-stage studies.

Spiration ® Valve System COPD Treatment Available to Highmark Blue Cross Blue Shield Members in Delaware, Pennsylvania, and West Virginia

Toronto, Ontario--(Newsfile Corp. - January 15, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company”), is pleased to announce that further to its press releases of December 18, 2020, and January 8, 2021, the Company has completed the second tranche of its non-brokered private placement financing (the “Offering”) through the issuance of 13,625,000 units (each, a “Unit”) at a price of $0.20 per Unit for gross proceeds of $2,725,000.

Growing pervasiveness of chronic disorders like cardiovascular diseases and cancers, rising acceptance of diagnostic imaging, along with surging demand for non-invasive therapeutic and diagnostic devices are the key factors driving the growth of global medical digital imaging systems market.